BioCryst Pharmaceuticals Inc. (BCRX) Trading Down 5.4%
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s share price was down 5.4% during mid-day trading on Wednesday . The stock traded as low as $4.34 and last traded at $4.39, with a volume of 1,108,431 shares trading hands. The stock had previously closed at $4.64.
Several equities research analysts have recently commented on BCRX shares. Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 9th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. Jefferies Group raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Wednesday, June 1st. FBR & Co reaffirmed a “buy” rating and set a $6.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, July 6th. Finally, JMP Securities lowered shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $8.22.
The stock’s market capitalization is $323.54 million. The stock has a 50 day moving average of $3.75 and a 200-day moving average of $3.08.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. The company earned $4.80 million during the quarter, compared to analyst estimates of $3.92 million. BioCryst Pharmaceuticals’s revenue for the quarter was down 81.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.06 EPS. On average, equities research analysts predict that BioCryst Pharmaceuticals Inc. will post ($1.03) earnings per share for the current fiscal year.
In other BioCryst Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 4,046,590 shares of the stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $5.00, for a total value of $20,232,950.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Thomas R. Staab II sold 5,864 shares of the stock in a transaction dated Friday, August 12th. The shares were sold at an average price of $5.18, for a total value of $30,375.52. Following the completion of the sale, the insider now directly owns 128,745 shares in the company, valued at approximately $666,899.10. The disclosure for this sale can be found here.
An institutional investor recently raised its position in BioCryst Pharmaceuticals stock. Morgan Stanley increased its position in shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) by 13.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,804 shares of the biotechnology company’s stock after buying an additional 12,646 shares during the period. Morgan Stanley owned 0.14% of BioCryst Pharmaceuticals worth $1,071,000 as of its most recent filing with the SEC.
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.